It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Gambogic acid (GA), a xanthonoid extracted from the resin of the tree, Garcinia hanburyi, was recently shown to exert anticancer activity in multiple studies, but the underlying action mechanism remains unclear. Here, we show that GA induces cancer cell death accompanied by vacuolation in vitro and in vivo. This GA-induced vacuolation in various cancer cells was derived from dilation of the endoplasmic reticulum (ER) and mitochondria, and was blocked by cycloheximide. These findings suggest that GA kills cancer cells by inducing paraptosis, a vacuolization-associated cell death. We found that megamitochondria formation, which arose from the fusion of swollen mitochondria, preceded the fusion of ER-derived vacuoles. GA-induced proteasomal inhibition was found to contribute to the ER dilation and ER stress seen in treated cancer cells, and megamitochondria formation was followed by mitochondrial membrane depolarization. Interestingly, GA-induced paraptosis was effectively blocked by various thiol-containing antioxidants, and this effect was independent of ROS generation. We observed that GA can react with cysteinyl thiol to form Michael adducts, suggesting that the ability of GA to covalently modify the nucleophilic cysteinyl groups of proteins may cause protein misfolding and subsequent accumulation of misfolded proteins within the ER and mitochondria. Collectively, our findings show that disruption of thiol proteostasis and subsequent paraptosis may critically contribute to the anti-cancer effects of GA.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Ajou University Graduate School of Medicine, Department of Biomedical Sciences, Suwon, Korea (GRID:grid.251916.8) (ISNI:0000 0004 0532 3933); Ajou University, Department of Biochemistry and Molecular Biology, Suwon, Korea (GRID:grid.251916.8) (ISNI:0000 0004 0532 3933)
2 Ajou University, Department of Biochemistry and Molecular Biology, Suwon, Korea (GRID:grid.251916.8) (ISNI:0000 0004 0532 3933)
3 Ajou University, Department of Pharmacy, Suwon, Korea (GRID:grid.251916.8) (ISNI:0000 0004 0532 3933)
4 Dankook University, Department of Pharmacy, Cheonan, Korea (GRID:grid.411982.7) (ISNI:0000 0001 0705 4288)
5 Chemical Data-Driven Research Center, Korea Research Institute of Chemical Technology, Daejeon, Korea (GRID:grid.29869.3c) (ISNI:0000 0001 2296 8192)
6 University of Ulsan College of Medicine, Asan Institute for Life Sciences, Department of Convergence Medicine, Asan Medical Center, Seoul, Korea (GRID:grid.267370.7) (ISNI:0000 0004 0533 4667)
7 Asan Medical Center, University of Ulsan College of Medicine, Center for Advancing Cancer Therapeutics, Department of Radiation Oncology, Seoul, Korea (GRID:grid.413967.e) (ISNI:0000 0001 0842 2126)




